Poor tolerability to ponatinib in Indian CML patients
نویسندگان
چکیده
منابع مشابه
Resistant mutations in CML and Ph+ALL – role of ponatinib
In 2012, ponatinib (Iclusig(®)), an orally available pan-BCR-ABL tyrosine kinase inhibitor (TKI) developed by ARIAD Pharmaceuticals, Inc., was approved by the US Food and Drug Administration for use in resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL). Ponatinib is the only approved TKI capable of inhibiting BCR-A...
متن کاملOptimizing tolerability of TKI therapy in CML.
Bosutinib is a dual SRC and ABL1 inhibitor with a unique binding mode that accommodates several BCR-ABL1 mutations that confer TKI resistance to imatinib, nilotinib, or dasatinib. In distinction to other inhibitors, bosutinib does not inhibit the platelet-derived growth factor (PDGF) receptors or KIT which might be associated with an individual safety profile. The design of the bosutinib phase ...
متن کاملEfficacy and Tolerability of Glucosamine - Chondroitin Sulphate - Methyl Sulfonyl Methane (MSM) in Osteoarthritis of Knee in Indian Patients
Background & Objective. Osteoarthritis is progressive degenerative disease resulting in significant affection of joints. Nonsteroidal anti-inflammatory drugs (NSAIDS) are widely used in this condition but are associated with significant side effects; hence the aim of this study was to evaluate the efficacy and tolerability of nutritional supplements such as Glucosamine, Chondroitin sulphate and...
متن کاملResponse to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be f...
متن کاملCombination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
The major mechanism of imatinib (IM) resistance of CML is the reactivation of ABL kinase either through BCR-ABL gene amplification or mutation. We investigated the cytotoxicity of a pan-ABL tyrosine kinase inhibitor, ponatinib, and a pan-histone deacetylase inhibitor, panobinostat, against IM-resistant CML cells in vitro. Two different IM-resistant cell lines, K562/IM-R1 and Ba/F3/T315I were ev...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood Advances
سال: 2020
ISSN: 2473-9529,2473-9537
DOI: 10.1182/bloodadvances.2020001944